Pembrolizumab-induced rash in a patient with angiosarcoma.

Qian, Justin; Kubicki, Shelby L; Curry, Jonathan L; Jahan-Tigh, Richard; Benjamin, Robert; Heberton, Meghan; Nelson, Kelly C

Qian, Justin; Kubicki, Shelby L; Curry, Jonathan L; Jahan-Tigh, Richard; Benjamin, Robert; Heberton, Meghan; Nelson, Kelly C.

Qian J; Baylor College of Medicine School of Medicine, Baylor College of Medicine, Houston, Texas.
Kubicki SL; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Curry JL; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jahan-Tigh R; Department of Dermatology, University of Texas Health Science Center at Houston, Houston, Texas.
Benjamin R; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Heberton M; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nelson KC; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

JAAD Case Rep ; 29: 21-24, 2022 Nov.

Article en En | MEDLINE | ID: mdl-36186410

Palabras clave

BP, bullous pemphigoid; LP, lichen planus; LPP, LP pemphigoides; PD-1; PD-1, programmed cell-death protein 1; PD-L1, programmed cell-death ligand 1; angiosarcoma; bullous pemphigoid; lichen planus; lichen planus pemphigoides; oncology; pembrolizumab; rash

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article